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Abstract: Successful treatment of psychiatric disorders, including bipolar disorder and 
schizophrenia, is complicated and is affected by a broad range of factors associated with the 
diagnosis, choice of treatment and social factors. In these patients, treatment management 
must focus on accurate and early diagnosis, to ensure that correct treatment is administered 
as soon as possible. In both disorders, the treatment of the disease in the acute phase must be 
maintained long term to provide continuous relief and normal function; the treatment choice 
in the early stages of the disease may impact on long-term outcomes. In schizophrenia, treat-
ment non-compliance is an important issue, with up to 50% of patients discontinuing treatment 
for reasons as diverse as efﬁ  cacy failure, social barriers, and more commonly, adverse events. 
Treatment non-compliance also remains an issue in bipolar disorder, as tolerability of mood 
stabilizers, especially lithium, is not always good, and combination treatments are frequent. In 
order to achieve an optimal outcome in which the patient continues with their medication life-
long, treatment should be tailored to each individual, taking into account treatment and family 
history, and balancing efﬁ  cacy with tolerability to maximize patient beneﬁ  t and minimize the 
risk of discontinuation. These case studies illustrate how treatment should be monitored, tailored 
and often changed over time to meet these needs.
Keywords: bipolar disorder, recurrence, treatment management, schizophrenia, non-compliance, 
adverse events
Introduction
Successful treatment of psychiatric disorders, such as bipolar disorder and schizo-
phrenia, should ideally result in long-term control in which the disease is managed 
effectively. However, successful treatment is complicated by a number of compound-
ing factors, such as compliance and drug-resistance phenomena (Altamura 1990). 
Of these, time to accurate diagnosis is a particular issue as this can delay initiation 
of the correct treatment for the patient (Berk et al 2007). Administration of effective 
treatment is essential both in the acute phase to manage the disease rapidly, but also in 
the long term to ensure that treatment beneﬁ  ts are maintained (Altamura et al 2000). 
Successful treatment can be considered to be one that provides the most effective 
balance between efﬁ  cacy and tolerability (Bowden 1995; Thomas 2007). While the 
initial treatment may be effective in managing acute symptoms of schizophrenia and 
manic or depressive episodes of bipolar disorder, continuous assessment of the patient 
is required to ensure optimal tolerability and efﬁ  cacy (Altamura 1992). It is recognized 
that maintaining the initial treatment is ideal; however, alternative or additional treat-
ments may be required at particular stages of the disease, as the course develops, to 
address any imbalance between efﬁ  cacy and tolerability. The need for such continu-
ous assessment and ﬂ  exibility in treatment is demonstrated by the high incidence of Neuropsychiatric Disease and Treatment 2008:4(1) 312
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treatment non-compliance in psychiatric disorders, which 
is a major factor in determining the outcomes of treatment 
(Altamura et al 2000; Dolder et al 2002; Thomas 2007). 
Sociodemographic factors, such as family history and 
employment status, are associated with poor treatment com-
pliance, while treatment-related factors, such as lack of efﬁ  -
cacy and adverse events and, particularly in bipolar disorder, 
disease symptoms (eg, poor insight and cognitive deﬁ  cits) 
may lead directly to discontinuation of therapy (Gray et al 
2002; Rettenbacher et al 2004; Linden et al 2006; Clatworthy 
et al 2007). The importance of adverse events is particularly 
true for schizophrenia, in which patients frequently receive 
high doses of antipsychotic drugs which affects compliance, 
particularly with ﬁ  rst generation antipsychotics (Altamura 
1990; Altamura et al 2000, 2007).
A further consideration is the presentation of pediatric 
and adolescent forms of psychiatric disorders which may 
differ somewhat in terms of symptoms, disease course, and 
treatment options from the corresponding adult disorders. 
This can be seen in pediatric bipolar disorder which is often 
characterized by the presence of mixed-mania and rapid 
cycling and a high degree of comorbidity with behavioral 
and attention disorders (Chang and Ketter 2001) – factors 
that contribute to difﬁ  culties in diagnosis. Similar problems 
are encountered in childhood onset schizophrenia which may 
be difﬁ  cult to differentiate from affective and personality 
disorders due to the predominance of negative symptoms 
(Masi et al 2006). Treatment of early and very early-onset 
schizophrenia is further complicated by differences in 
response to pharmacological therapy compared with adults, a 
problem exacerbated by a lack of clinical trials in this patient 
sub-population (Young and Findling 2004).
This article explores some of the challenges of success-
fully treating patients with bipolar disorder and schizophre-
nia. In both of these conditions successful treatment is often 
hindered by misdiagnosis, poor treatment compliance and 
inter-patient variability in treatment efﬁ  cacy and tolerability. 
These issues are highlighted through the use of case studies 
giving an insight into how to maximize clinical success in 
difﬁ  cult-to-treat patients with diverse psychiatric disorders.
Managing treatment options 
in bipolar disorder
Mania is the basis for the diagnosis of bipolar disorder. Pure 
euphoric mania is usually easy to identify; but other types of 
presentation, such as psychotic mania, or when symptoms of 
mania and depression occur together as a mixed episode, are 
frequently misdiagnosed. Mixed hypomania is more frequent 
in patients with type I bipolar disorder and has been reported 
in 57% of patients (Suppes et al 2005). Such co-occurring 
symptoms can make diagnosis of bipolar disorder difﬁ  cult, 
such that there is often a delay between the onset of symptoms 
and correct diagnosis (Hantouche et al 2006). Inaccurate 
diagnosis commonly results in patients receiving incorrect 
therapies, which may delay successful treatment of the initial 
episodes, and in some cases may even exacerbate them, for 
example causing rapid-cycling states (Sachs et al 2007). The 
following case study illustrates the difﬁ  culties associated with 
the treatment of a patient presenting with mixed symptoms 
of bipolar disorder.
Clinical case study
A 36-year-old female with no previous psychiatric history 
was ﬁ  rst hospitalized due to an acute episode with psychotic 
symptoms (reference and grandiosity delusions), high 
anxiety, irritability, global insomnia and agitation. She was 
diagnosed with brief psychotic disorder which was treated 
with thioridazine up to 200 mg/day. Four months later, she 
suffered a major depression that was treated by a private 
psychiatrist with ﬂ  uoxetine up to 40 mg/day. After 1 month, 
the depression progressed to a mixed state with high irritabil-
ity, anxiety, demanding behavior, insomnia, and depressive 
thoughts. Fluoxetine was stopped and the patient was treated 
with low doses of haloperidol (up to 5 mg/day). During the 
following weeks, the patient progressively went to a new 
depressive episode with hypothymia (low mood), tiredness, 
hypersomnia, and psychomotor inhibition. Haloperidol was 
tapered off but major depression lasted a further 3 months. 
The patient visited another psychiatrist who started imipra-
mine up to 150 mg/day to treat the depression, this resulted in 
a fast improvement of the depressive episode. About 2 months 
later, the patient experienced another acute episode, very 
similar to the ﬁ  rst one, that required hospitalization. At this 
time, approximately 2 years after the ﬁ  rst episode, she was 
diagnosed with bipolar disorder type I, manic episode with 
congruent psychotic symptoms. Following the diagnosis, the 
patient was treated with lithium (1000 mg/day; serum level 
0.87 meq/L) for the following 1.5 years; however, she still 
experienced both depressive and hypomanic episodes of an 
irritable nature. Combined treatment with lithium and antide-
pressants (ﬁ  rst ﬂ  uoxetine up to 40 mg/day; then imipramine 
up to 150 mg/day) improved the severity of the episodes, 
removing psychotic tendencies, but the frequency of episodes 
increased to 2-week cycles of depression following by 1 week 
of hypomania and 1–2 weeks of euthymia. To address this 
rapid cycling, carbamazepine up to 600 mg/day was added Neuropsychiatric Disease and Treatment 2008:4(1) 313
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to the treatment regimen; however, this caused skin rashes 
and was discontinued after 2 weeks of treatment.
At this point, the patient ﬁ  rst came to our clinic. Sub-
clinical hypothyroidism was detected and was treated with 
thyroxine 100 µg/day, antidepressants were discontinued and 
the patient was switched from lithium to sodium valproate 
2000 mg/day over a period of 3 weeks. Lithium was tapered 
off and valproate was started at 1000 mg/day, resulting in 
serum levels of 27.1 µg/mL. Valproate was increased to 
2000 mg/day, resulting in serum levels of 75 µg/mL. After 
two milder cycles, the patient was stabilized and began to 
recover pre-morbid functioning.
The patient maintained this treatment regimen for 5 years 
during which time she experienced weight gain. Patient dis-
satisfaction led to the gradual replacement of valproate with 
lamotrigine, up to 200 mg/day. Three months after switching 
the medication, the patient suffered a mixed depression with 
hypothymia, apathy, depressive thoughts, mood lability, irri-
tability and insomnia. The previous regimen with valproate 
was restarted; the patient stabilized and was euthymic with 
only occasional anxiety in response to family problems. 
This good global functioning currently allows the patient to 
care for her mother, who suffers from an advanced mixed 
dementia, and her father. Other than weight gain, valproate 
was generally well tolerated and no other adverse events 
were experienced.
Discussion
The patient described provides a clear example of the compli-
cations surrounding successful treatment of bipolar disorder. 
Correct diagnosis of bipolar disorder is often delayed by over 
5 years due to the presence of mixed symptoms (Hantouche 
et al 2006; Berk et al 2007). This prevents correct treat-
ment from being administered and can affect the long-term 
outcomes of the disease (Berk et al 2007). The diagnosis of 
bipolar disorder type I in this patient was delayed by 2 years 
due to previous misdiagnoses of brief psychiatric disorder and 
depression, during which time the patient was mostly suffer-
ing an affective episode which resulted in two hospitalizations 
and complete dysfunction. Therefore, although the time of 
misdiagnosis was relatively short, the clinical consequences 
of the misdiagnosis were severe.
Mood stabilizers are the mainstay of treatment for bipo-
lar disorder; these include lithium and sodium valproate 
(Bowden et al 2005, 2006). Sodium valproate has demon-
strated improved efﬁ  cacy over lithium in treating mixed 
episodes in bipolar disorder, with better outcomes reported 
for depressive episodes and overall function (Bowden et al 
2005). Other anticonvulsants used in the treatment of bipolar 
disorder include carbamazepine and lamotrigine.
Rapid cycling is a common observation in bipolar disorder, 
and is associated with reduced treatment responses, poorer 
long-term prognosis and a probable higher suicide risk than 
patients who do not display rapid cycling (Schneck 2006). 
Furthermore, these patients often experience more depressive 
than manic episodes. As observed in this patient, subclinical 
hypothyroidism can be related to rapid cycling (Papadimitriou 
et al 2005). This ﬁ  nding and the substitute hormone treatment 
helped the patient to stabilize. Rapid cycling is estimated to 
occur in 14%–53% of patients (Maj et al 1994; Tondo and 
Baldessarini 1998; Suppes et al 2001), of which over 70% 
have been attributed to a poor response to lithium. (Dunner 
and Fieve 1974; Bowden 1995; Calabrese et al 2005). Long-
term open clinical trials with sodium valproate in patients 
with rapid cycling have demonstrated initial good responses, 
with few recurrent episodes (McElroy et al 1988; Calabrese 
and Delucchi 1990). This supports suggestions that sodium 
valproate has a broader spectrum of use than lithium (Bowden 
1995). Although the most recent data from a long-term study 
by Calabrese and colleagues did not support the hypothesis 
that sodium valproate was more effective than lithium for 
the treatment of rapid cycling in bipolar disorder, there was 
a trend towards a greater advantage with sodium valproate 
in terms of mood symptoms and adverse events (Calabrese 
et al 2005). Furthermore, sodium valproate has demonstrated 
antidepressive effects in bipolar disorder, preventing or delay-
ing the onset of depressive episodes (Ghaemi and Goodwin 
2001; Bowden et al 2005).
Carbamazepine has been reported to be effective in 
some patients with rapid cycling bipolar disorder (Post et al 
1986; Joyce 1988; Tondo et al 2003), especially when used 
in combination with lithium (Baethge et al 2005). However, 
this combination caused a rash in the patient presented here 
and was subsequently discontinued; this is in agreement with 
studies showing an increase in adverse events with combined 
carbamazapine/lithium therapy (Baethge et al 2005). A 
small number of reports have demonstrated effectiveness of 
lamotrigine in rapid-cycling, especially when combined with 
valproate (da Rocha et al 2007). This was the rationale for 
converting the patient from valproate to lamotrigine following 
the onset of weight gain. However, lamotrigine monotherapy 
was associated with a regression of symptoms in this patient. 
The reintroduction of valproate improved the severity of the 
episodes, leading to good global functioning and stabiliza-
tion, but problems with weight gain continued. Referral to 
a dietician and subsequent life-style changes regarding diet Neuropsychiatric Disease and Treatment 2008:4(1) 314
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and exercise regimens may improve weight gain in patients 
with bipolar disorder (Chue and Kovacs 2003).
Outcomes of bipolar disorder can also be negatively 
inﬂ  uenced by incorrect administration of mood stabilizers 
and antidepressants (Goldberg et al 2007), and rapid cycling 
can be induced or worsened by antidepressants in the absence 
of a mood stabilizer (Sachs et al 2007). It is possible that 
both the use of a high dose of ﬂ  uoxetine (40 mg/day vs the 
standard 20 mg/day) and the combination of lithium and 
antidepressants in the patient described here exacerbated 
the hypomanic episodes and led to the presentation of the 
rapid cycling state.
Early and accurate diagnosis of bipolar disorder is essen-
tial to ensure that correct treatment is received at the earliest 
opportunity since incorrect treatment can negatively affect 
outcomes. As demonstrated in the case presented, correct 
treatment of bipolar disorder can be successful in the long 
term once this is achieved.
Non-compliance and treatment 
choices in schizophrenia
Treatment compliance is essential for the long-term control 
of schizophrenia. Despite advances in the newer atypical 
(second-generation) antipsychotic therapies, treatment non-
compliance is reported to occur in up to 50% of patients with 
schizophrenia (Fenton et al 1997; Dolder et al 2002; Gray 
et al 2002; Rettenbacher et al 2004; Thomas 2007), with 
discontinuation rates of 74% within 18 months reported in 
some studies (Lieberman et al 2005). The impact of non-
compliance is far reaching in maintenance therapy, with 
non-compliant patients often experiencing impaired long-
term outcomes including higher relapse rates and the need 
for rehospitalization (Fenton et al 1997; Ascher-Svanum et al 
2006). Factors associated with treatment non-compliance are 
multifactoral including sociodemographic variables (age, 
occupation, social status or level of education), attitudes 
of patients and carers/family towards the illness and treat-
ment, illness-related issues such as psychopathology and 
comorbidities, and treatment issues such as adverse events 
(Rettenbacher et al 2004; Linden et al 2006). One of the most 
common reasons cited for non-compliance of treatment in 
schizophrenia are adverse events (Naber and Karow 2001). 
The spectrum of adverse events with antipsychotic therapy 
is varied and is dependent on the choice of drug. Among the 
most common adverse events with typical antipsychotics 
are extrapyramidal symptoms (EPS), sexual dysfunction, 
and weight gain. The newer atypical antipsychotic drugs 
have been associated with fewer EPS (Geddes et al 2000; 
Davis et al 2003; Lieberman et al 2005); however, there have 
been increasing concerns that these drugs lead to metabolic 
side effects including diabetes, dyslipidemia, and obesity 
(Mortimer et al 2003; Meyer and Koro 2004; Peuskens 
et al 2007; Spurling et al 2007). Switching non-compliant 
patients to alternative antipsychotics may improve compli-
ance by better balancing efﬁ  cacy and tolerability (Peuskens 
2002; Linden et al 2006; Linden et al 2007). The following 
case study illustrates the issues surrounding the treatment of 
schizophrenia, demonstrating that many changes in therapy 
may be required to determine the most effective treatment 
for any individual.
Clinical case study
A 40-year-old male presented with the appearance of perse-
cutory delusions with sub-threshold depressive symptoms. 
At the time of presentation, the patient was receiving aripip-
razole 15 mg/day, which had a good impact on negative 
symptoms and social abilities. However, the aripiprazole 
was causing gastrointestinal side effects including severe 
nausea and constipation leading to occasional dissatisfac-
tion and a lack of treatment compliance. The patient was 
also experiencing concomitant obesity with a body weight 
of 96 kg and glucose intolerance (156 mg/dL). The patient 
was diagnosed with paranoid schizophrenia according to 
DSM-IV criteria and structured clinical interview. This was 
episodic in nature with residual symptoms occurring between 
acute episodes. This diagnosis was based on the prevalence 
of organized delusions and hallucinations, and the separation 
of several acute psychotic episodes with periods of negative 
and depressive symptoms.
Treatment history revealed that the patient was predis-
posed to develop EPS and had a variable response to prior 
antipsychotic therapy. From the age of onset at 30-years, the 
patient’s initial treatment with haloperidol up to 10 mg/day 
for 2 years managed positive symptoms and was used in 
maintenance therapy. However, the development of negative 
symptoms and emergence of EPS led to a change in therapy 
to risperidone (8 mg/day). After 1 year, the risperidone dose 
was reduced to 4 mg/day because of further EPS, but this 
resulted in the reappearance of positive symptoms and treat-
ment was subsequently switched to olanzapine 20 mg/day. 
The patient received olanzapine for 1.5 years during which 
time positive symptoms regressed. However, during this 
time the patient experienced a signiﬁ  cant weight gain of 
approximately 10 kg. This weight gain led to the patient 
switching treatment from olanzapine to aripiprazole up to 
15 mg/day.Neuropsychiatric Disease and Treatment 2008:4(1) 315
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After 2 years of aripiprazole therapy, the patient presented 
at our clinic as described above. The patient was converted 
to amisulpride at a starting dose of 400 mg/day, because of 
psychotic recurrences and low tolerability to other antipsy-
chotic drugs. Amisulpride was gradually increased to an 
effective dose of 800 mg/day. This approach was undertaken 
to avoid any risk of treating abruptly at the optimal effective 
dose in the acute phase of the illness given the patient’s very 
complex medical history. There was regular monitoring of 
blood pressure (weekly), electrocardiogram and prolactin 
plasma levels (at baseline, at month 1, and every 3 months). 
All the parameters remained within normal levels during 
treatment, with the exception of prolactin which showed an 
increase at month 3 (43 ng/mL), that persisted at the other 
timepoints. The patient was not converted to clozapine due 
to the recent signiﬁ  cant weight gain with olanzapine and his 
current obesity status, since the potential risk of developing 
a metabolic syndrome with clozapine is similar to that with 
olanzapine in terms of weight gain. Given that the patient 
had previously shown the reappearance of positive symptoms 
with doses  4 mg/day of risperidone, quetiapine was not 
considered useful since there was the possibility of worsen-
ing positive symptoms because of the weaker blockade of 
dopamine (D2) receptors.
Treatment with amisulpride led to remission of psychotic 
episodes with an improvement in depressive symptoms and 
somatizations. The patient is still being monitored and will 
remain on this treatment until complete remission of psy-
chotic episodes, depressive symptoms and somatizations. 
Globally, the treatment with amisulpride well tolerated. There 
was an improvement in the patient’s glucose intolerance (156 
mg/dL vs 102 mg/dL at baseline and month 6, respectively). 
The patient was referred to a dietology specialist in order to 
manage obesity, after 6 months receiving amisulpride the 
patient’s body weight had reduced to 92 kg.
Discussion
Treatment non-compliance has a signiﬁ  cant impact on the 
outcomes of schizophrenia. Many of the currently available 
antipsychotic therapies have comparable efﬁ  cacy in the 
treatment of symptoms in the acute phase; however, their 
tolerability proﬁ  les can vary (Davis et al 2003; Mortimer 
et al 2003). The presented case study demonstrates such vari-
ability, with the patient experiencing a range of complications 
under different therapies. This was further complicated by 
the emergence of different symptoms of the disease during 
long-term therapy. At the time of presentation, the patient was 
receiving aripiprazole, having already previously received 
therapy with haloperidol, risperidone and olanzapine. While 
poor compliance to aripiprazole at presentation was attributed 
to the gastrointestinal side effects, a large number of external 
factors are associated with treatment non-compliance in 
patients with schizophrenia, including social status, occupa-
tion and social support (Linden et al 2006). This patient was 
unemployed with no social support with a family history 
of mental health issues; his father suffered from alcohol 
dependence and his sister had probable schizoaffective dis-
order, bipolar type. These additional contributing factors to 
compliance should be assessed on an individual basis when 
considering antipsychotic therapy.
Amisulpride was considered to be the best choice of 
antipsychotic therapy for the patient, based on the low 
tolerability to other antipsychotic therapies and the presen-
tation of depressive symptoms. Switching to amisulpride 
has previously been demonstrated to improve treatment 
compliance (Linden et al 2006; Kim et al 2007; Linden 
et al 2007; Spurling et al 2007). This may be related to the 
improved tolerability proﬁ  le associated with amisulpride 
when comparing weight gain, metabolic control and EPS, 
which were particular issues for the patient illustrated 
here. As with most atypical antipsychotics, amisulpride is 
associated with a low incidence of EPS (Wetzel et al 1998; 
Herrera-Estrella et al 2005; Nuss et al 2007). Furthermore, 
clinical studies with amisulpride and olanzapine have dem-
onstrated that patients receiving amisulpride have less weight 
gain and less increase in blood glucose than those receiving 
olanzapine (Mortimer 2004; Mortimer et al 2004; Peuskens 
et al 2007). Amisulpride has clear beneﬁ  ts over risperidone 
with regard to weight gain as well (Sechter et al 2002). 
Importantly, these studies clearly demonstrate comparable 
efﬁ  cacy between the different agents, in agreement with an 
earlier meta-analysis of the efﬁ  cacy of atypical antipsychot-
ics (Davis et al 2003).
Although amisulpride has demonstrated good efﬁ  cacy 
in the treatment of positive symptoms (Sechter et al 2002; 
Mortimer et al 2004; Herrera-Estrella et al 2005; Nuss et al 
2007), it is also effective for the treatment of negative and 
depressive symptoms of schizophrenia (Speller et al 1997; 
Muller et al 2002; Peuskens et al 2002; Mortimer et al 2004; 
Herrera-Estrella et al 2005; Murphy et al 2006; Kim et al 
2007; Nuss et al 2007), having clear beneﬁ  ts over olanzapine 
and risperidone with improved symptom control and longer 
time to depressive episodes (Peuskens et al 2002; Mortimer 
2004; Kim et al 2007). However, olanzapine has also been 
attributed to have treatment effects on negative symptoms 
(Lecrubier et al 2006).Neuropsychiatric Disease and Treatment 2008:4(1) 316
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The prolactin-elevating effects of amisulpride are well 
recognized, therefore prolactin plasma levels were measured 
regularly in this patient. In this case, no clinical symptoms 
of hyperprolactinemia were detected. Nevertheless, patients 
treated with amisulpride should be observed and asked 
about symptoms such as sexual dysfunction, galactorrhea 
and amenorrhea.
The balance between efﬁ  cacy and tolerability is an essen-
tial aspect when considering antipsychotic treatment and the 
establishment of a positive tolerability/efﬁ  cacy ratio should be 
an integral determinant in the choice of treatment. Whilst the 
efﬁ  cacy of treatment is important, maintaining good long-term 
tolerability is essential to ensure that the treatment is continued 
and be of beneﬁ  t. There are considerable differences in the 
tolerability of different antipsychotic therapies, and there may 
also be considerable difference in the response of different 
patients to these drugs. The tolerability/efﬁ  cacy ratio therefore 
provides a measure to help to tailor antipsychotic therapy 
individually; it is essential that both aspects be considered 
when starting or switching therapies in schizophrenia. This 
case illustrates the beneﬁ  t of continuously monitoring and 
changing treatment of schizophrenia to achieve this optimal 
treatment ratio (Altamura et al 2007).
Conclusions
Early and accurate diagnosis is essential for the successful 
treatment of psychiatric disorders. As well as having a beneﬁ  -
cial impact on treatment of the acute phase of the disease, it 
can also affect long-term outcomes of treatment. For example, 
a high incidence of treatment non-compliance is reported 
across a range of psychiatric disorders, many of which are 
attributed to treatment effects such as lack of efﬁ  cacy or 
adverse events. This is highlighted by the two cases reported 
here, where misdiagnosis and inappropriate drug therapy 
resulted in poor treatment outcomes in both bipolar disorder 
and schizophrenia. Although the speciﬁ  c factors contribut-
ing to successful treatment may vary between psychiatric 
disorders, the approach to treatment should be very similar. 
Diagnosis and treatment should be tailored to the individual 
patient, taking into account a detailed family and treatment 
history, and ensuring that the tolerability is adequate to 
maximize long-term compliance of medication.
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